Immune-Boosting cocktail shows promise in slowing ALS
NCT ID NCT06307301
First seen Apr 29, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This early-stage trial tested whether a combination of two drugs, abatacept and interleukin-2, is safe for people with ALS. The goal was to increase the number and activity of regulatory T cells, which are immune cells that may help slow disease progression. Five participants were enrolled, and researchers monitored side effects and changes in immune cell levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.